arrow
B

Behzad Amoozgar

loma linda university health
H指数:14
被引数:600

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma:

在风险较高的早期霍奇金淋巴瘤中,省略放射治疗与较差的疾病控制相关

2026-01-010
OAAI
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure

基于先前CD19定向CAR T暴露的大B细胞淋巴瘤中Tafasitamab和Lenalidomide的治疗效果

2025-11-180
OAAI
Age and Tumor Stage Interplay in Intrahepatic Cholangiocarcinoma: Prognostic Factors, Mortality Trends, and Therapeutic Implications from a SEER-Based Analysis

年龄和肿瘤分期在肝内胆管癌中的相互作用:基于SEER分析的预后因素、死亡率趋势及治疗意义

2025-01-250
OA
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
2024-11-141
OAAI
Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

真实世界中Ciltacabtagene autoleucel与Idecabtagene vicleucel治疗复发/难治性多发性骨髓瘤的疗效与安全性比较:一项回顾性意向性治疗分析

BLOOD
IF23.1
2024-11-050
PRE
Impact of Allogeneic Stem Cell Transplant on Safety and Outcomes of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Patients with Multiple Myeloma (MM)

异基因干细胞移植对多发性骨髓瘤 (MM) 患者嵌合抗原受体T细胞 (car-t) 治疗的安全性和结局的影响

2024-10-180
OAAI